You have 9 free searches left this month | to do more
Showing 1 - 25 of
144 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Completed
  • Bioequivalence
  • Treatment A: Acalabrutinib tablet
  • Treatment B: Acalabrutinib capsule
  • Glendale, California
  • +2 more
2021-06-01
Jun 1, 2021
U
Recruiting
  • Central Nervous System Lymphoma
  • Chapel Hill, North Carolina
  • +1 more
2022-03-24
Mar 24, 2022
U
Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
2021-08-04
Aug 4, 2021
W
Withdrawn
  • Chronic Lymphocytic Leukemia
  • CLL/SLL
  • Acalabrutinib
  • New York, New York
    Weill Cornell Medicine
2022-03-25
Mar 25, 2022
U
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Colchester, Essex, United Kingdom
  • +2 more
2021-10-20
Oct 20, 2021
D
Recruiting
  • Post-transplant Lymphoproliferative Disorder
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
2022-02-02
Feb 2, 2022
D
Recruiting
  • Central Nervous System Lymphoma
  • +2 more
  • Acalabrutinib
  • Boston, Massachusetts
  • +1 more
2022-01-05
Jan 5, 2022
A
Active, not recruiting
  • Mantle Cell Lymphoma (MCL)
  • Acalabrutinib in combination with BR
  • Acalabrutinib in combination with VR
  • Louisville, Kentucky
  • +14 more
2022-01-19
Jan 19, 2022
U
Recruiting
  • Mantle Cell Lymphoma
  • Acalabrutinib
  • R-CHOP chemotherapy
  • Vancouver, British Columbia, Canada
  • +3 more
2022-03-17
Mar 17, 2022
W
Active, not recruiting
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-02-02
Feb 2, 2022
S
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Seattle, Washington
    Swedish Cancer Institute
2021-03-01
Mar 1, 2021
A
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib (Arm A)
  • Acalabrutinib (Arm B)
  • Bethesda, Maryland
    Research Site
2022-01-19
Jan 19, 2022
U
Active, not recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Rochester, New York
    University of Rochester
2022-02-07
Feb 7, 2022
W
Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-03-14
Mar 14, 2022
F
Recruiting
  • Recurrent Moderate-Severe Chronic Graft Versus Host Disease
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Acalabrutinib
  • Questionnaire Administration
  • Tampa, Florida
  • +3 more
2021-12-22
Dec 22, 2021
S
Withdrawn
  • Lymphoma
  • Leukemia
  • Acalabrutinib, tacrolimus, methotrexate
  • (no location specified)
2022-02-20
Feb 20, 2022
C
Recruiting
  • Autoimmune Hemolytic Anemia
  • +3 more
  • Acalabrutinib
  • Duarte, California
    City of Hope Medical Center
2022-03-09
Mar 9, 2022
M
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib
  • Obinutuzumab
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-18
Nov 18, 2021
J
Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +3 more
  • Acalabrutinib
  • Los Angeles, California
  • +2 more
2022-03-17
Mar 17, 2022
F
Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-31
Mar 31, 2022
A
Completed
  • Hepatic Impairment
  • +2 more
  • acalabrutinib
  • Miami, Florida
  • +2 more
2021-08-16
Aug 16, 2021